Obesity and prostate cancer tissue study
Part of Cancer, Hormones & metabolism, Kidney & urinary clinical trials.
This study looks at how obesity might affect prostate cancer growth. It uses tissue samples to understand the role of certain metabolites in the tumor, which could lead to better treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with prostate cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at proteins in the blood of people having bariatric surgery to understand how the surgery affects the body. It may help find ways to improve outcomes.
This study looks at tiny particles released from fat tissue in people with and without obesity. It aims to understand differences that might help explain obesity-related health problems.
This trial explores how certain natural fats in the body might affect diseases linked to obesity, such as breast cancer. It aims to see if these fats can reduce inflammation and improve health.
This study looks at how prostate cancer shows up on scans and how those imaging findings relate to treatment and outcomes. It may help doctors better predict risk and guide care, especially for people with higher risk or early or suspected prostate cancer.
This trial collects tumor samples from men with prostate cancer to study the bacteria and other microbes inside the tumor. It aims to learn how these microbes might affect the cancer and treatment.
This study tests whether a structured exercise and nutrition program can improve obesity-related frailty and overall function in people with advanced prostate cancer who are taking hormone therapy (ADT). It may help with strength, mobility, and healthier body weight during/after ADT.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.